April 18 (Reuters) - Prometic Life Sciences Inc PLI.TO
* FDA confirms Prometic's PBI-4050 IPF clinical trial design
* Prometic Life Sciences Inc - Prometic to also conduct placebo controlled phase 2/3 PBI-4050 monotherapy clinical trial
* Prometic Life Sciences Inc - FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with Nintedanib Source text for Eikon: Further company coverage: PLI.TO